Company / R&D Expense
Caris Life Sciences, Inc. R&D Expense History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$101.6M
FY2025
5-year range
$101.6M / $116.9M
FY2023-FY2025
Trend
-10.8%
vs FY2024
Sector context
#55 of 110
Health Care
What the data says
At $102M, Caris Life Sciences, Inc.'s r&d expense ranks #55 of 110 in the Health Care sector. Declined from $117M to $102M over the past 2 years.
Based on SEC 10-K filings.
$102M in FY2025.
Declined from $117M to $102M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#55 of 110 in Health CareTop 50% of 110This company $101.6M Sector average $298.2M
▼
-65.9% below sector average
Key checks
Key Insights
- In FY2025, r&d expense decreased 10.8% year-over-year.
- Ranks #55 out of 110 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.08 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $101.6M | -10.8% |
| FY2024 | $113.9M | -2.5% |
| FY2023 | $116.9M | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026